Skip to main content
Top
Published in: Cost Effectiveness and Resource Allocation 1/2009

Open Access 01-12-2009 | Research

Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina

Authors: Adolfo Rubinstein, Sebastián García Martí, Alberto Souto, Daniel Ferrante, Federico Augustovski

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2009

Login to get access

Abstract

Background

Chronic diseases, represented mainly by cardiovascular disease (CVD) and cancer, are increasing in developing countries and account for 53% of chronic diseases in Argentina. There is strong evidence that a reduction of 50% of the deaths due to CVD can be attributed to a reduction in smoking, hypertension and hypercholesterolemia. Generalized cost-effectiveness analysis (GCE) is a methodology designed by WHO to inform decision makers about the extent to which current or new interventions represent an efficient use of resources. We aimed to use GCE analysis to identify the most efficient interventions to decrease CVD.

Methods

Six individual interventions (treatment of hypertension, hypercholesterolemia, smoking cessation and combined clinical strategies to reduce the 10 year CVD Risk) and two population-based interventions (cooperation between government, consumer associations and bakery chambers to reduce salt in bread, and mass education strategies to reduce hypertension, hypercholesterolemia and obesity) were selected for analysis. Estimates of effectiveness were entered into age and sex specific models to predict their impact in terms of age-weighted and discounted DALYs saved (disability-adjusted life years). To translate the age- and sex-adjusted incidence of CVD events into health changes, we used risk model software developed by WHO (PopMod). Costs of services were measured in Argentine pesos, and discounted at an annual rate of 3%. Different budgetary impact scenarios were explored.

Results

The average cost-effectiveness ratio in argentine pesos (ARS$) per DALY for the different interventions were: (i) less salt in bread $151; (ii) mass media campaign $547; (iii) combination drug therapy provided to subjects with a 20%, 10% and 5% global CVD risk, $3,599, $4,113 and $4,533, respectively; (iv) high blood pressure (HBP) lowering therapy $7,716; (v) tobacco cessation with bupropion $ 33,563; and (iv) high-cholesterol lowering therapy with statins $ 70,994.

Conclusion

Against a threshold of average per capita income in Argentina, the two selected population-based interventions (lowering salt intake and health education through mass-media campaigns) plus the modified polypill strategy targeting people with a 20% or greater risk were cost-effective. Use of this methodology in developing countries can make resource-allocation decisions less intuitive and more driven by evidence.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mathers CD LA, Stein C, Fat DM, Rao C: Deaths and disease burden by cause: global burden of disease estimates for 2001 by World Bank Country Groups. Working paper 18. Bethesda, MD: Disease Control Priorities Project. 2005. Mathers CD LA, Stein C, Fat DM, Rao C: Deaths and disease burden by cause: global burden of disease estimates for 2001 by World Bank Country Groups. Working paper 18. Bethesda, MD: Disease Control Priorities Project. 2005.
2.
go back to reference Defunciones por causas, Argentina, 2004. Dirección de Estadísticas e Información. Ministerio de Salud de la Nación Defunciones por causas, Argentina, 2004. Dirección de Estadísticas e Información. Ministerio de Salud de la Nación
3.
go back to reference Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367: 1747–1757. 10.1016/S0140-6736(06)68770-9PubMedCrossRef Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367: 1747–1757. 10.1016/S0140-6736(06)68770-9PubMedCrossRef
4.
go back to reference Primera Encuesta Nacional de Factores de Riesgo. Primera Edición – Buenos Aires. Ministerio de Salud de la Nación 2006. Primera Encuesta Nacional de Factores de Riesgo. Primera Edición – Buenos Aires. Ministerio de Salud de la Nación 2006.
5.
go back to reference Schargrodsky H, Hernandez-Hernandez R, Champagne BM, Silva H, Vinueza R, Silva Aycaguer LC, Touboul PJ, Boissonnet CP, Escobedo J, Pellegrini F, Macchia A, Wilson E, CARMELA Study Investigators: CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med 2008, 121: 58–65. 10.1016/j.amjmed.2007.08.038PubMedCrossRef Schargrodsky H, Hernandez-Hernandez R, Champagne BM, Silva H, Vinueza R, Silva Aycaguer LC, Touboul PJ, Boissonnet CP, Escobedo J, Pellegrini F, Macchia A, Wilson E, CARMELA Study Investigators: CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med 2008, 121: 58–65. 10.1016/j.amjmed.2007.08.038PubMedCrossRef
6.
go back to reference Preventing chronic diseases: a vital investment WHO global report. Geneva 2005. Preventing chronic diseases: a vital investment WHO global report. Geneva 2005.
7.
go back to reference Strong K, Mathers C, Leeder S, Beaglehole R: Preventing chronic diseases: how many lives can we save? Lancet 2005, 366: 1578–1582. 10.1016/S0140-6736(05)67341-2PubMedCrossRef Strong K, Mathers C, Leeder S, Beaglehole R: Preventing chronic diseases: how many lives can we save? Lancet 2005, 366: 1578–1582. 10.1016/S0140-6736(05)67341-2PubMedCrossRef
8.
go back to reference Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K: The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007, 370: 1929–1938. 10.1016/S0140-6736(07)61696-1PubMedCrossRef Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K: The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007, 370: 1929–1938. 10.1016/S0140-6736(07)61696-1PubMedCrossRef
9.
go back to reference Murray CJLLA: The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge. 1st edition. Edited by: Murray CJL, Lopez AD. MA: Harvard University Press; 1996. Murray CJLLA: The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge. 1st edition. Edited by: Murray CJL, Lopez AD. MA: Harvard University Press; 1996.
10.
go back to reference World Health Organization: The World Health Report: Reducing risks, Promoting Healthy Life. Geneva: World Health Organization; 2002. World Health Organization: The World Health Report: Reducing risks, Promoting Healthy Life. Geneva: World Health Organization; 2002.
11.
go back to reference Rubinstein A, Belizan M, Discacciati V: Are economic evaluations and health technology assessments increasingly demanded in times of rationing health services? The case of the Argentine financial crisis. Int J Technol Assess Health Care 2007, 23: 169–176. 10.1017/S0266462307070274PubMedCrossRef Rubinstein A, Belizan M, Discacciati V: Are economic evaluations and health technology assessments increasingly demanded in times of rationing health services? The case of the Argentine financial crisis. Int J Technol Assess Health Care 2007, 23: 169–176. 10.1017/S0266462307070274PubMedCrossRef
12.
go back to reference Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, Lawes CM, Evans DB: Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003, 361: 717–725. 10.1016/S0140-6736(03)12655-4PubMedCrossRef Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, Lawes CM, Evans DB: Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003, 361: 717–725. 10.1016/S0140-6736(03)12655-4PubMedCrossRef
13.
go back to reference Gaziano TA, Opie LH, Weinstein MC: Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006, 368: 679–686. 10.1016/S0140-6736(06)69252-0PubMedCrossRefPubMedCentral Gaziano TA, Opie LH, Weinstein MC: Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006, 368: 679–686. 10.1016/S0140-6736(06)69252-0PubMedCrossRefPubMedCentral
14.
go back to reference World Health Organization: Making choices in health: WHO Guide to Cost-Effectiveness Analysys. Edited by: Tan-Torres Edejer T, et al. WHO Library; 2003. World Health Organization: Making choices in health: WHO Guide to Cost-Effectiveness Analysys. Edited by: Tan-Torres Edejer T, et al. WHO Library; 2003.
15.
go back to reference Relevamiento del uso de sal en los productos de panaderías artesanales de la República Argentina e implementación de acciones de desarrollo, tecnológicas, de asistencia técnica y extensión con el objeto de bajar su utilización y consumo. Programa VIGI+A 2005. Relevamiento del uso de sal en los productos de panaderías artesanales de la República Argentina e implementación de acciones de desarrollo, tecnológicas, de asistencia técnica y extensión con el objeto de bajar su utilización y consumo. Programa VIGI+A 2005.
16.
go back to reference He FJ, MacGregor GA: How far should salt intake be reduced? Hypertension 2003, 42: 1093–1099. 10.1161/01.HYP.0000102864.05174.E8PubMedCrossRef He FJ, MacGregor GA: How far should salt intake be reduced? Hypertension 2003, 42: 1093–1099. 10.1161/01.HYP.0000102864.05174.E8PubMedCrossRef
17.
go back to reference Sellers DE, Crawford SL, Bullock K, McKinlay JB: Understanding the variability in the effectiveness of community heart health programs: a meta-analysis. Soc Sci Med 1997, 44: 1325–1339. 10.1016/S0277-9536(96)00263-8PubMedCrossRef Sellers DE, Crawford SL, Bullock K, McKinlay JB: Understanding the variability in the effectiveness of community heart health programs: a meta-analysis. Soc Sci Med 1997, 44: 1325–1339. 10.1016/S0277-9536(96)00263-8PubMedCrossRef
18.
go back to reference The Canadian Hypertension Education Program Recommendations 2004. The Canadian Hypertension Education Program Recommendations 2004.
19.
go back to reference Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Bmj 2003, 326: 1423. 10.1136/bmj.326.7404.1423PubMedCrossRefPubMedCentral Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Bmj 2003, 326: 1423. 10.1136/bmj.326.7404.1423PubMedCrossRefPubMedCentral
20.
go back to reference Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Adult Treatment Panel III 2002. Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Adult Treatment Panel III 2002.
21.
go back to reference Hughes J, Stead L, Lancaster T: Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004, CD000031. Hughes J, Stead L, Lancaster T: Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004, CD000031.
22.
go back to reference Encuesta de Tabaquismo en grandes ciudades de Argentina – 2004. Ministerio de Salud y Ambiente de la Nación 2005. Encuesta de Tabaquismo en grandes ciudades de Argentina – 2004. Ministerio de Salud y Ambiente de la Nación 2005.
24.
go back to reference Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97: 1837–1847.PubMedCrossRef Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97: 1837–1847.PubMedCrossRef
25.
go back to reference Lauer JA, Rohrich K, Wirth H, Charette C, Gribble S, Murray CJ: PopMod: a longitudinal population model with two interacting disease states. Cost Eff Resour Alloc 2003, 1: 6. 10.1186/1478-7547-1-6PubMedCrossRefPubMedCentral Lauer JA, Rohrich K, Wirth H, Charette C, Gribble S, Murray CJ: PopMod: a longitudinal population model with two interacting disease states. Cost Eff Resour Alloc 2003, 1: 6. 10.1186/1478-7547-1-6PubMedCrossRefPubMedCentral
26.
go back to reference Gimpel N SV, Rubinstein A: Quality Management of Hypertension in Primary Care: Do physicians treat blood pressure level or patients' risk? Quality in Primary Care 2006, 14: 211–217. Gimpel N SV, Rubinstein A: Quality Management of Hypertension in Primary Care: Do physicians treat blood pressure level or patients' risk? Quality in Primary Care 2006, 14: 211–217.
27.
go back to reference Jamison D: 'Investing in health', in D Jamison et al., Disease Control Priorities in Developing Countries. Volume 3–36. 2nd edition. New York: Oxford University Press; 2006. Jamison D: 'Investing in health', in D Jamison et al., Disease Control Priorities in Developing Countries. Volume 3–36. 2nd edition. New York: Oxford University Press; 2006.
28.
go back to reference Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R: Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet 2007, 370: 2044–2053. 10.1016/S0140-6736(07)61698-5PubMedCrossRef Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R: Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet 2007, 370: 2044–2053. 10.1016/S0140-6736(07)61698-5PubMedCrossRef
29.
go back to reference Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, Lozano R, Rodgers A: Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet 2007, 370: 2054–2062. 10.1016/S0140-6736(07)61699-7PubMedCrossRef Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, Lozano R, Rodgers A: Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet 2007, 370: 2054–2062. 10.1016/S0140-6736(07)61699-7PubMedCrossRef
30.
go back to reference Batussen RMAT, Tan Torres T, et al.: Generalized cost-effectiveness analysis: a guide. Global Programme on Evidence for Health Policy. Geneva: WHO; 2002. Batussen RMAT, Tan Torres T, et al.: Generalized cost-effectiveness analysis: a guide. Global Programme on Evidence for Health Policy. Geneva: WHO; 2002.
32.
go back to reference Ezzati M, Lopez AD, Rodgers A, Hoorn S, Murray CJ: Selected major risk factors and global and regional burden of disease. Lancet 2002, 360: 1347–1360. 10.1016/S0140-6736(02)11403-6PubMedCrossRef Ezzati M, Lopez AD, Rodgers A, Hoorn S, Murray CJ: Selected major risk factors and global and regional burden of disease. Lancet 2002, 360: 1347–1360. 10.1016/S0140-6736(02)11403-6PubMedCrossRef
33.
go back to reference Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364: 937–952. 10.1016/S0140-6736(04)17018-9PubMedCrossRef Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364: 937–952. 10.1016/S0140-6736(04)17018-9PubMedCrossRef
34.
go back to reference Kannel WB: Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000, 13: 3S-10S. 10.1016/S0895-7061(99)00252-6PubMedCrossRef Kannel WB: Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000, 13: 3S-10S. 10.1016/S0895-7061(99)00252-6PubMedCrossRef
35.
go back to reference Brownson : Chronic Disease Epidemiology and Control. 2nd edition. American Public Health Association; 1998. Brownson : Chronic Disease Epidemiology and Control. 2nd edition. American Public Health Association; 1998.
36.
go back to reference Bronner LL, Kanter DS, Manson JE: Primary prevention of stroke. N Engl J Med 1995, 333: 1392–1400. 10.1056/NEJM199511233332106PubMedCrossRef Bronner LL, Kanter DS, Manson JE: Primary prevention of stroke. N Engl J Med 1995, 333: 1392–1400. 10.1056/NEJM199511233332106PubMedCrossRef
37.
go back to reference Law MR, Wald NJ, Morris JK, Jordan RE: Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003, 326: 1427. 10.1136/bmj.326.7404.1427PubMedCrossRefPubMedCentral Law MR, Wald NJ, Morris JK, Jordan RE: Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003, 326: 1427. 10.1136/bmj.326.7404.1427PubMedCrossRefPubMedCentral
Metadata
Title
Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina
Authors
Adolfo Rubinstein
Sebastián García Martí
Alberto Souto
Daniel Ferrante
Federico Augustovski
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Cost Effectiveness and Resource Allocation / Issue 1/2009
Electronic ISSN: 1478-7547
DOI
https://doi.org/10.1186/1478-7547-7-10

Other articles of this Issue 1/2009

Cost Effectiveness and Resource Allocation 1/2009 Go to the issue